Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

MLA

James N. Ingle, et al. Impact of C-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831. Aug. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....975968abe9d833a77009ae7de375acbd&authtype=sso&custid=ns315887.

APA

James N. Ingle, Robert B. Jenkins, Edith A. Perez, Lyndsay Harris, Leila A. Kutteh, Kathleen S. Tenner, Darren L. Riehle, Beiyun Chen, Julie Gralow, Wilma L. Lingle, Monica M. Reinholz, Ann E. McCullough, Peter A. Kaufman, Silvana Martino, GW Sledge, Amylou C. Dueck, Nancy E. Davidson, Xochiquetzal J. Geiger, & Karla V. Ballman. (2013). Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.

Chicago

James N. Ingle, Robert B. Jenkins, Edith A. Perez, Lyndsay Harris, Leila A. Kutteh, Kathleen S. Tenner, Darren L. Riehle, et al. 2013. “Impact of C-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831,” August. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....975968abe9d833a77009ae7de375acbd&authtype=sso&custid=ns315887.